A new era in iron chelation therapy: The design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients

Hemoglobin

Volumn 33, Issue 5, 2009, Pages 332-338

  Kontoghiorghes, George J ^a  

^a Postgraduate Research Institute of Science Technology Environment and Medicine Limassol   (Cyprus)

Author keywords

Deferasirox (DFRA); Deferiprone (L1); Deferoxamine (DFO); Normal iron stores; Optimal dose protocols; Thalassemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ANAPHYLAXIS; BLOOD TRANSFUSION; CAUSE OF DEATH; CLINICAL PROTOCOL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; FERRITIN BLOOD LEVEL; GOLD STANDARD; HEART; HUMAN; IRON CHELATION; IRON KINETICS; IRON OVERLOAD; LIVER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; SIDE EFFECT; SURVIVAL; UNSPECIFIED SIDE EFFECT;

BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL PROTOCOLS; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; PYRIDONES; SIDEROPHORES; THALASSEMIA;

EID: 70350643863     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903217182     Document Type: Conference Paper

References (18)

1. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30(2):239-249.
2. Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2):41-47.
3. Kontoghiorghes GJ. Advances in oral iron chelation in man. Int J Haematol. 1992;55(1):27-38.
4. Kattamis A, Kassou C, Berdousi H, et al. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88(12):1423-1425.
5. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007;138(3):407-421.
6. Kolnagou A, Michaelides Y, Kontos C, et al. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin. 2008;32(1- 2):17-28.
7. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: advances with deferiprone/deferoxamine combination and concerns on deferasirox's safety, efficacy and costs. Hemoglobin. 2008;32(1-2):1-15.
8. Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin. 2008;32(6):608-615.
9. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinations. Curr Med Chem. 2005;12(23):2663-2681.
10. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in b-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
11. Nisbet-Brown E, Olivieri NF, Giardina PJV, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-1602.
12. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-3737.
13. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to bthalassemia. J Clin Pharmacol. 2003;43(6):565-572.
14. Kontoghiorghes GJ, Kolnagou A. Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Curr Med Chem. 2005;12(23):2695-2709.
15. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;ii(8653):27-29.
16. Tefler P, Goen PG, Christou S, et al. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91(9): 1187-1192.
17. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in b-thalassaemia with the oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one. Br Med J. 1987;295(6612):1509-1512.
18. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93(5):741-752.